- Home
- MSGS vs MRUS Comparison
MSGS vs MRUS Comparison
Compare MSGS & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSGS
- MRUS
- Stock Information
- Founded
- MSGS 1879
- MRUS 2003
- Country
- MSGS United States
- MRUS Netherlands
- Employees
- MSGS N/A
- MRUS N/A
- Industry
- MSGS Services-Misc. Amusement & Recreation
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- MSGS Consumer Discretionary
- MRUS Health Care
- Exchange
- MSGS Nasdaq
- MRUS Nasdaq
- Market Cap
- MSGS 5.3B
- MRUS 5.1B
- IPO Year
- MSGS N/A
- MRUS 2016
- Fundamental
- Price
- MSGS $214.39
- MRUS $94.86
- Analyst Decision
- MSGS Buy
- MRUS Buy
- Analyst Count
- MSGS 7
- MRUS 18
- Target Price
- MSGS $258.83
- MRUS $93.72
- AVG Volume (30 Days)
- MSGS 191.9K
- MRUS 2.3M
- Earning Date
- MSGS 10-31-2025
- MRUS 10-31-2025
- Dividend Yield
- MSGS N/A
- MRUS N/A
- EPS Growth
- MSGS N/A
- MRUS N/A
- EPS
- MSGS N/A
- MRUS N/A
- Revenue
- MSGS $1,025,367,000.00
- MRUS $56,606,000.00
- Revenue This Year
- MSGS N/A
- MRUS $51.77
- Revenue Next Year
- MSGS $4.80
- MRUS N/A
- P/E Ratio
- MSGS N/A
- MRUS N/A
- Revenue Growth
- MSGS N/A
- MRUS 57.54
- 52 Week Low
- MSGS $173.26
- MRUS $33.19
- 52 Week High
- MSGS $237.99
- MRUS $95.30
- Technical
- Relative Strength Index (RSI)
- MSGS 40.22
- MRUS 77.93
- Support Level
- MSGS $225.22
- MRUS $94.59
- Resistance Level
- MSGS $229.19
- MRUS $95.30
- Average True Range (ATR)
- MSGS 5.06
- MRUS 0.34
- MACD
- MSGS -1.10
- MRUS -0.98
- Stochastic Oscillator
- MSGS 27.48
- MRUS 51.11
About MSGS Madison Square Garden Sports Corp. (New)
Madison Square Garden Sports Corp owns and operates a portfolio of assets featuring some of the recognized sports teams, including the Knicks of the NBA and the Rangers of the NHL. It generates revenue from several sources: ticket sales and a portion of suite rental fees at The Garden and others. It has one operating and reportable segment and one reporting unit for goodwill impairment testing purposes.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.